Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Treasury Shares (2022 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Treasury Shares data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Treasury Shares fell 55.18% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 55.18%, while the annual FY2025 figure was $2.1 million, 55.18% down from the prior year.
  • Treasury Shares reached $2.1 million in Q4 2025 per INDV's latest filing, down from $5.4 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.9 million in Q4 2022 and bottomed at $1.2 million in Q4 2023.
  • Average Treasury Shares over 4 years is $3.8 million, with a median of $4.5 million recorded in 2025.
  • Peak YoY movement for Treasury Shares: plummeted 80.39% in 2023, then surged 304.2% in 2024.
  • A 4-year view of Treasury Shares shows it stood at $5.9 million in 2022, then tumbled by 80.39% to $1.2 million in 2023, then soared by 304.2% to $4.7 million in 2024, then plummeted by 55.18% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.1 million in Q4 2025, $5.4 million in Q3 2025, and $2.8 million in Q2 2025.